Version 1
: Received: 1 March 2021 / Approved: 2 March 2021 / Online: 2 March 2021 (14:25:54 CET)
How to cite:
Lewczuk, K.; Konopińska, J.; Joablonska, J.; Mariak, Z.; Rękas, M. XEN Glaucoma Implant for Refractory Glaucoma Management: Results and Complications during a 2-year Follow-up. Preprints2021, 2021030096
Lewczuk, K.; Konopińska, J.; Joablonska, J.; Mariak, Z.; Rękas, M. XEN Glaucoma Implant for Refractory Glaucoma Management: Results and Complications during a 2-year Follow-up. Preprints 2021, 2021030096
Lewczuk, K.; Konopińska, J.; Joablonska, J.; Mariak, Z.; Rękas, M. XEN Glaucoma Implant for Refractory Glaucoma Management: Results and Complications during a 2-year Follow-up. Preprints2021, 2021030096
APA Style
Lewczuk, K., Konopińska, J., Joablonska, J., Mariak, Z., & Rękas, M. (2021). XEN Glaucoma Implant for Refractory Glaucoma Management: Results and Complications during a 2-year Follow-up. Preprints. https://doi.org/
Chicago/Turabian Style
Lewczuk, K., Zofia Mariak and Marek Rękas. 2021 "XEN Glaucoma Implant for Refractory Glaucoma Management: Results and Complications during a 2-year Follow-up" Preprints. https://doi.org/
Abstract
The aim of this study was to analyze surgical and refractive outcomes of XEN glaucoma implant (Allergan, an Abbvie company, Irvine, CA, USA), a minimally invasive surgical device for the treatment of refractory glaucoma. A retrospective chart review of eyes that received XEN Gel Stent placement from December 2014 to October 2019 was conducted. Intraocular pressure (IOP) change, best corrected visual acuity (BCVA), change in glaucoma medications, frequency of slit lamp revision procedures, and frequency of secondary glaucoma surgeries were the primary outcomes. Seventy-two subjects were included in the study: 32 (44%) males and 40 (56%) females. The mean follow-up time was 26.87 ± 15.33 months. The mean IOP before surgery was 24.82 ± 8.03 mmHg and decreased to 17.45 ± 5.84 mmHg at the end of the study, MD = -7.48, CI95 [-10.04; -4.93], p < 0.001. The mean decrease from baseline was 23%. Before surgery BCVA was 0.38±0.30 and at the end of the follow-up period it had improved to 0.47±0.37, MD = 0.09, CI95 [0.04; 0.13], p < 0.001. Additional procedures (fluorouracil injection, Bleb needling) were performed in 11/72 patients (15%). Further glaucoma surgery was necessary for 23.9%% of the patients. Implantation of XEN Gel Stent is both safe and effective for lowering IOP in refractory glaucoma patients.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
